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The study evaluated the safety, efficacy and acceptability of Implanon (etonogestrel) subdermal
implant contraceptive amongst its acceptors.
This was part of an on going prospective longitudinal study that involved 32 women out of 46
sexually active healthy informed volunteers recruited from our family planning clinic between February and
March 2007. All the subjects received the single rod subdermal implant Implanon which contains 68mg
etonogestrel. Data on socio-demographic characteristics, menstrual pattern, haematological indices, weight,
blood pressure, side effects and user's satisfaction were collected and analysed. The subjects served as their
own control.
The mean age and parity were 33.9 ± 5.2 years and 3.1 ± 1.7 respectively. The mean weight was 71.4 ±
12.0kg at pre-insertion. At 6 months the weight reduced to a non significant (p < 0.13) mean value of 70.0 ±
10.5kg and increased to a non significant (p < 0.88) mean value of 71.5 ± 11.6kg at 12 months. The mean
systolic and diastolic blood pressures did not show statistical significant changes at 6 months follow up
(p<0.17/0.64). However at 12 months there were significant but within normal reductions (p < 0.003/0.05) in
the systolic and diastolic blood pressures. The side effects were menstrual abnormalities. Eighteen (56.3%), 1
(3.1%) and 13 (40.6%) reported reduced, increased and combinations of bleeding patterns respectively. No
participant had normal cycle. Other experiences were headache, 4 (12.5%) and reduced libido 3 (9.4%). The
mean packed and white blood cell concentrations did not show statistical significant changes at 6 and 12
months follow up. At 12 months there was statistical significant increase (p<0.04) in the mean ± SD platelet
count (205312.5 ± 75694.8per ul) when compared with the pre-insertion mean value (176343.8 ±52945.3per
ul). One acceptor had thrombocytopenia without any untoward effect.
Two subjects discontinued method on account of menorrhagia and headache. The efficacy and continuation
rate were 100% and 93.8% respectively. All the clients received adequate information about the method and
most of them were satisfied with it at follow up.
Implanon was an effective, safe and acceptable method of contraception amongst its acceptors.
Menstrual abnormalities were the major side effects which most of the subjects found tolerable with adequate
counseling. The reduced platelet concentration of the one acceptor would require follow up to ascertain the
trend.
Implanon implant, safety, efficacy and acceptability
INTRODUCTION
Implanon subdermal progestogen (etonogestrel) is a
second generation implant developed as a need to
reduce some of the problems associated with the six
implant system, Norplant . It is an effective long
term reversible method of contraception , suitable
for many women across different reproductive ages
. Even though it has been in use for some time , it







The most common side effect of Implanon is
disruption of menstrual cycle which has led to
discontinuation amongst its acceptors in various
studies . In spite of these, no patient had been
reported to have anaemia with its use . This is
relevant in developing countries where many women
already have nutritional deficiencies coupled with
anaemia . Other common drug related adverse
events reported include headache, weight gain, acne
and depression . The contraceptive action
of Implanon is mainly by inhibition of ovulation that













Packed cell volume (PCV)
White blood cell concentration (WBC)
Platelets concentration
Continuation rate, efficacy, acceptability
The age range and mean of the subjects were 24-45
years and 33.9 ± 5.2 years. Parity range and mean
were 0-6 and 3.1 ± 1.7 respectively. 31 (96.9%) of the
subjects were married and had formal education,
with 15 (46.9%), 15 (46.9%) and 1 (6.2%) having
tertiary, secondary and primary levels of education
respectively. One client was unmarried and had
secondary level of education.
The mean weight was 71.4 ± 12.0 kg at pre-insertion.
There were no statistical significant changes in mean
weight at six (70.0 ± 10.5kg) and twelve months
(71.5 ± 11.6kg) when compared with pre-insertion
mean value. (Table 1). Fifteen 46.9% subjects had
increased weight, 14 (43.7%) had a weight reduction
while 3 (9.4%) had no weight changes.
The systolic and diastolic blood pressures did not
show any statistical significant changes at 6 months
of study (p< 0.17/0.64). However at 12 months
follow up there were statistical significant reductions
(0.003/0.05) in the mean values of the systolic and
diastolic blood pressure which were within normal
limits (Table 1).
The main adverse events reported were menstrual
abnormalities where 18 (56.3%), 1 (3.1%) and 13
(40.6%) subjects reported reduced, increased and
combinations of bleeding patterns respectively.
There was no subject with normal menstrual cycle in
the reference periods (Tables 2 and 3).
At the time of admission into the study the mean
value of the PCV was 37.3 ± 2.5%. There were no
statistical significant changes at six and twelve
months of study (p<0.83 and p< 0.22 respectively
(Table 4).
The mean concentration of white blood cells at pre-
insertion was 5275 ± 1124.5per µl. There were no
statistical significant changes at six and twelve
months of study (p<0.06 and p<0.43) respectively
(Table 4).
The mean concentration of the platelets at pre-
insertion was 176343.8 ± 52945.3per µl at insertion.
This rose to a non significant mean normal
concentration at 6 months of 203875 ± 73603.0 per
µl (p<0.1) and a significant increase p<0.04) at 12
months of study (Table 4). One subject had platelet
concentrations of <100000 at 12 months with
concentrations of 89000per µl.
Two subjects discontinued use at 6months because of
menorrhagia and headache giving a continuation rate
before 2004 was 100% . It has been found to have
satisfactory profile with quick return to
fertility .
At this initial stage of Implanon introduction into our
contraceptive method mix, it is important to
document its safety, efficacy and acceptability
amongst the users.
Forty six sexually active, healthy informed
volunteers aged between 24-45 years were recruited
from our Family Planning Clinic of the University of
Benin Teaching Hospital, Benin-City, Edo State,
Nigeria between February and March 2007. One
hundred and ninety clients accepted family planning
methods during the period out of which fifty clients
chose Implanon. The forty six who consented to
participate in the study had not received any
injectable contraceptive within 6 months preceding
recruitment and they were all having regular normal
menstrual cycles. All the acceptors were given a
calendar each, to keep daily record of menstrual
bleeding events. The coding used for bleeding events
were zero “0” for no bleeding 'S' for spotting (defined
as scanty vaginal bleeding that did not require
sanitary protection) and “X” for vaginal bleeding that
required sanitary protection. Data analysis for the
bleeding patterns was based on completed 90 day
interval for reference period .
Venous blood (5mls) was collected from each subject
from the contra lateral arm and placed in a tube
containing EDTA anticoagulant for the estimation of
packed cell volume (PCV), platelets and white blood
cells (WBC) concentrations. Blood samples were
collected at pre-insertion and at 6 and 12 months
follow up. Each participant served as her own
control.
Data on socio demographic characteristics, weight,
blood pressure, side effects, and user's satisfaction
were also collected and analysed.
Each subject received Implanon, a single rod
subdermal implant, containing 68mg of etonogestrel.
The haematological indices were evaluated using
Abacus junior (Diatron Ltd 2003) haematology
analyzer. It uses the impedance method (also known
as coulter method) to count.
Thirty two (32) subjects who had complete records at
12 months were analysed. Paired t-test was used for
statistical analysis. The level of significance was set
at p<0.05. The remaining clients even though were
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6 months 12 months
Weight 71.4 ± 12.0 70.0 ± 10.5 71.5 ±11.6












P-value - 0.17/0.64 0.003/0.05
of the 32 acceptors as 93.8%. Other adverse events
reported were headache 5 (12.2%), reduced libido 3
(7.3%). The efficacy was 100% as no subject became
pregnant during the 12 months period. The users
were satisfied with the method (Table 5).
Table1:
Table 2:
Mean weight (mean ±SD) kg and Mean
Blood Pressure (mean ± SD) mmHg of Implanon
Acceptors at 6 and 12 months of Study.
Reduced Bleeding Irregularities of 32
Subjects during the Reference Periods (1 period
1-90 days, 2 period 91-180 days, 3 period 181-




Table 4: Haematological Parameters of Subjects (mean
± SD): Pre-insertion 6 and 12 months of follow up.
Table 3:
Table 5:
Increased Bleeding Irregularities in 32
Subjects during the Reference Periods (1 period
1-90 days, 2 period 91-180 days, 3 period 181-





























































b. Low risk of
pregnancy
c. Long duration of
action





4 No negative feelings about
the method
5 Recommendation of the
method to a friend
6 Usage of a second set of
implant for contraception


























The study has shown that the mean age of the subjects
as well as the parity distribution were within those
reported in the literature . The women in the
study had either reduction, increase or no weight
change without any statistical significant difference
when compared to the pre-insertion mean weight.
Other studies had documented either no change in
weight or increase in weight . Implanon is a
derivative of 19 nortestosterone which actions are anti
oestrogenic and androgenic. The weight gain observed
may have been a consequence of the anabolic effect of
the method in addition to a normal increase in weight
over time .
Experiences from studies have shown no changes in
blood pressure while one
study found a normal diastolic blood pressure
followed by a decline in systolic blood pressure after 6
months of study. This study showed statistical
significant reduction but within normal limits in the
systolic and the diastolic blood pressure at 12 months
follow up. This trend is advantageous as the women are
not predisposed to hypertensive disease.
The most common adverse experience reported by
acceptors of Implanon was menstrual disruption
which had led to discontinuation of use . In this
current study the subjects reported reduced, increased
and combination of both reduced and increased
bleeding patterns. Similar observation has also been
reported in the literature .
Hormonal contraceptive methods interfere with the
pituitary ovarian axis that controls the menstrual cycle.
The combined oral contraceptive pill is able to regulate
and simulate normal menstruation because of its
oestrogen content unlike the progestogen only
contraceptives hence the bleeding irregularities
associated with them. One subject discontinued
Implanon at 6months because of frequent bleeding and
spotting episodes. No participant discontinued because
of reduced bleeding. The analysis of bleeding patterns
in those who discontinued the use of Implanon showed
that they had experienced more prolonged and frequent
bleeding. However women who had amenorrhoea
were unlikely to discontinue Implanon use . The
apparent tolerance of irregularities of the menstrual
cycle by our clients may be due to effective counseling
at the time of insertion. The importance of counseling
has been highlighted in implant users where the
overall acceptability of the method improved.
Inspite of the irregular menstrual abnormalities
experienced, the packed cell volume of the acceptors
were normal. Other reports have found similar
changes . The white blood cell concentration did
not show statistical significant changes over the
months of follow up. Studies conducted had
shown that the effects of Implanon on haemostatic
system are not only small, but also not indicative of a
change towards either coagulation or fibrinolysis. In













significant but normal mean normal value at 12
months. There was one participant that had
thrombocytopenia without associated bleeding
abnormalities.
Other side effects reported were headache and
reduction in libido which are method related and have
also been reported . One patient discontinued
because of persistent headache.
The continuation rate at 12 months was 93.8%. Similar
high continuation rate has also been reported . The
efficacy was 100%. Many other studies had reported a
Pearl Index of 0.0. However no contraceptive method
is 100% efficacious and very small number of
pregnancies even after correct insertion of Implanon
had been reported .
In conclusion Implanon subdermal implant produced
bleeding irregularities amongst the acceptors which
was well tolerated and no participant became anaemic.
Implanon was an acceptable and effective method of
contraceptive with satisfactory safety profile amongst
the users.The thrombocytopenia experienced by one of
the participants is however worrisome and needs
follow up to establish the trend.
We acknowledge the cooperation of the participants in
this study and thank the Management of University of
Benin Teaching Hospital, Benin-City, Edo State,
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